摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methyl-5-methoxypyridin-3-amine | 1104455-29-9

中文名称
——
中文别名
——
英文名称
2-methyl-5-methoxypyridin-3-amine
英文别名
5-Methoxy-2-methylpyridin-3-amine
2-methyl-5-methoxypyridin-3-amine化学式
CAS
1104455-29-9
化学式
C7H10N2O
mdl
MFCD18250733
分子量
138.169
InChiKey
NIZHNEQMBILCQO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    290.0±35.0 °C(Predicted)
  • 密度:
    1.103±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.285
  • 拓扑面积:
    48.1
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 2,4-DIAMINO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2,4-DIAMINO-PYRIMIDINE
    申请人:ASTRAZENECA AB
    公开号:WO2009010794A1
    公开(公告)日:2009-01-22
    The invention concerns compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, Q, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation ofsuch compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.
    本发明涉及式(I)化合物,或其药用可接受盐,其中R1、Q、R3和R4如描述中定义。本发明还涉及制备此类化合物的方法、包含它们的药物组合物以及它们在制造用作抗增殖剂的药物中的应用,用于预防或治疗对EphB4激酶抑制敏感的肿瘤或其他增殖性疾病。
  • NOVEL PYRIMIDINE DERIVATIVES 965
    申请人:Barlaam Bernard Christophe
    公开号:US20090054428A1
    公开(公告)日:2009-02-26
    The invention concerns compounds of Formula I, or a pharmaceutically acceptable salt thereof, where R 1 , Q, R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.
    该发明涉及公式I的化合物,或其药学上可接受的盐,其中R1,Q,R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法,包含它们的制药组合物以及它们在制造用于作为抗增殖剂用于预防或治疗对EphB4激酶抑制敏感的肿瘤或其他增殖性疾病的药物的用途。
  • BICYCLIC NITROGENATED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
    申请人:Shionogi & Co., Ltd
    公开号:EP3527568A1
    公开(公告)日:2019-08-21
    Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. A compound represented by Formula (I): wherein Z1 is C(R4) or the like; R4 is a hydrogen atom or the like; Z2 is C(R5a)(R5a') or the like; the dashed line represents the presence or absence of a bond; when the dashed line represents the presence of a bond, then R5a' is absent; R5a and R5a' are each independently a hydrogen atom or the like; Ring Q is a substituted or unsubstituted 5-membered non-aromatic heterocycle or the like; Y1 is O or the like; R2a is a group represented by the formula: -(C(R2a')(R2b'))n-R1; R2b is a hydrogen atom or the like; R2a' and R2b' is each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; n is an integer from 0 to 4; and m is an integer from 0 to 4, or a pharmaceutically acceptable salt thereof.
    本文提供了一种对 P2X7 受体具有拮抗活性的新型化合物,以及一种对 P2X7 受体具有拮抗活性的药物组合物。由式(I)代表的化合物: 其中Z1是C(R4)或类似物;R4是氢原子或类似物;Z2是C(R5a)(R5a')或类似物;虚线表示键的存在或不存在;当虚线表示键的存在时,则R5a'不存在;R5a和R5a'各自独立地是氢原子或类似物;环Q是取代或未取代的5元非芳杂环或类似物;Y1是O或类似物;R2a是由式表示的基团:-(C(R2a')(R2b'))n-R1; R2b 是氢原子或类似物; R2a'和 R2b'各自独立地是氢原子或类似物; R1 是取代或未取代的芳香族碳环或类似物; X 是 N(R7a)或类似物;R7a 是氢原子或类似物;R3 是取代或未取代的芳香族羰基或类似物;n 是 0 至 4 的整数;和 m 是 0 至 4 的整数,或其药学上可接受的盐。
  • Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same
    申请人:Shionogi & Co., Ltd.
    公开号:US11066409B2
    公开(公告)日:2021-07-20
    Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.
    本文提供了一种对 P2X7 受体具有拮抗活性的新型化合物,以及一种对 P2X7 受体具有拮抗活性的药物组合物。该化合物由式(I)表示: 其中符号在说明书中定义,或其药学上可接受的盐。
  • BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    申请人:Shionogi & Co., Ltd.
    公开号:US20200048257A1
    公开(公告)日:2020-02-13
    Provided are a novel compound having an antagonistic activity for the P2X 7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X 7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-